UH Seidman癌症中心第一阶段试验测试BAFF CAR T细胞,这是针对复发病人的一种新的多种间皮瘤治疗。 Phase 1 trial at UH Seidman Cancer Center tests BAFF CAR T-cells, a new multiple myeloma treatment, for relapsed patients.
UH Seidman癌症中心第一阶段试验测试BAFF CAR T细胞,这是针对复发病人的三种受体(BAFF-R、BAMA和TACI)的一种新的多细胞治疗。 A Phase 1 trial at UH Seidman Cancer Center tests BAFF CAR T-cells, a new multiple myeloma treatment targeting three receptors (BAFF-R, BCMA, and TACI) for relapsed patients. 由Leland Metheny博士领导的试验旨在确定第二阶段试验的安全剂量,并评估BAFF CAR T细胞的活性,涉及20名患者. Led by Dr. Leland Metheny, the trial aims to determine a safe dose for Phase II trials and evaluate BAFF CAR T-cells' activity, involving 20 patients. 通过与卢米纳里治疗机构达成协议,新疗法提供了更多的治疗选择,减少了抗原脱逃的风险。 The novel therapy offers more treatment options and reduces the risk of antigen escape, conducted through an agreement with Luminary Therapeutics.